Constellation Pharmaceuticals Lands $22,000,000 Series B Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f00f10e9-b226-4d8e-9dc2-aa36a26b3b3f&Preview=1 -
Date
6/2/2010 -
Company Name
Constellation Pharmaceuticals -
Mailing Address
148 Sidney Street Cambridge, MA 02139 -
Company Description
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. -
Website
http://www.constellationpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$22,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will be used to advance the development of Constellation’s pipeline of compounds towards the clinic. These funds will also enable Constellation to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease. -
M&A Terms
-
Venture Investor
SR One -
Venture Investor
Third Rock Ventures -
Venture Investor
Venrock -
Venture Investor
The Column Group -
Venture Investor
Altitude Life Science Ventures
